EX-23.1 3 otlk-20200930ex2313a8c80.htm EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors
Outlook Therapeutics, Inc.:

We consent to the incorporation by reference in the Registration Statements (Nos. 333-211362, 333-216081, 333-223064, 333-229685,  333-234024, 333-236471 and 333-283318) on Form S-8, (Nos. 333-223063 and 333-231922) on Form S-3 and (Nos. 333-209011, 333-212351, 333-216610, 333-230791 and 333-237607) on Form S-1 of Outlook Therapeutics, Inc. of our report dated December 23, 2020, with respect to the consolidated balance sheets of Outlook Therapeutics, Inc. as of September 30, 2020 and 2019, and the related consolidated statements of operations, convertible preferred stock and stockholders’ equity (deficit), and cash flows for the years then ended and related notes (collectively, the consolidated financial statements), which report appears in the September 30, 2020 annual report on Form 10-K of Outlook Therapeutics, Inc.

Our report dated December 23, 2020 contains an explanatory paragraph that states that Outlook Therapeutics, Inc. has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit of $289.7 million as of September 30, 2020 that raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.


Philadelphia, Pennsylvania
December 23, 2020